fluconazole has been researched along with Agranulocytosis in 13 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 9.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy." | 7.80 | Fluconazole associated agranulocytosis and thrombocytopenia. ( Ludlow, SP; Pasikhova, Y, 2014) |
| " Although the patient was on prophylaxis with fluconazole and she did not respond to amphotericin B, there was an excellent response to itraconazole which allowed the transplant without any Aspergillus infection during both the transplant and the post-transplant periods." | 7.68 | [Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia]. ( Alvarez Blanco, A; Alvarez, C; Floristán, F; Hernández, I; Hernández, J; Ponton, J; Sarcía-Ruiz, JC, 1993) |
| "We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic." | 7.68 | Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 7.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "Fluconazole is a commonly prescribed antifungal agent with a favorable safety profile." | 5.31 | Fluconazole-induced agranulocytosis with eosinophilia. ( Shriner, K; Wong-Beringer, A, 2000) |
| "A patient who was diagnosed as having agranulocytosis and thrombocytopenia after treatment with fluconazole was investigated and recovered after withdrawal of the antifungal therapy." | 5.28 | Agranulocytosis during treatment with fluconazole. ( Katahira, H; Matsushima, T; Murakami, H; Sakura, T; Sawamura, M; Tamura, J; Tsuchiya, J, 1992) |
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 5.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy." | 3.80 | Fluconazole associated agranulocytosis and thrombocytopenia. ( Ludlow, SP; Pasikhova, Y, 2014) |
| " Although the patient was on prophylaxis with fluconazole and she did not respond to amphotericin B, there was an excellent response to itraconazole which allowed the transplant without any Aspergillus infection during both the transplant and the post-transplant periods." | 3.68 | [Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia]. ( Alvarez Blanco, A; Alvarez, C; Floristán, F; Hernández, I; Hernández, J; Ponton, J; Sarcía-Ruiz, JC, 1993) |
| "We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic." | 3.68 | Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993) |
| "To investigate the potential use of fluconazole for prevention and treatment of disseminated candidiasis in granulocytopenic patients, its in vivo antifungal activity was studied in three models of disseminated candidiasis in persistently granulocytopenic rabbits: acute, subacute, and chronic disseminated candidiasis." | 3.68 | Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. ( Aoki, S; Bacher, J; Lee, J; Mechinaud, F; Pizzo, PA; Rubin, M; Walsh, TJ, 1990) |
| "We compared the efficacies of the new triazole antifungal drugs fluconazole and itraconazole with that of amphotericin B in vitro and in an animal model of systemic candidiasis in normal and neutropenic mice." | 3.67 | Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. ( Mattie, H; van Furth, R; Van t Wout, JW, 1989) |
| "Fluconazole was as effective as amphotericin B in preventing severe local and disseminated fungal disease (one documented and one highly suspected infection in each group of patients)." | 2.67 | A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. ( Branger, J; Dekker, AW; Rozenberg-Arska, M; Verhoef, J, 1991) |
| "Fluconazole is a new orally absorbed antifungal azole which is effective in the treatment of mucosal and systemic infections caused by Candida, cryptococci and other fungi." | 2.67 | Management of fungal infection in neutropenic patients with fluconazole. ( Brammer, KW, 1990) |
| "Fluconazole is a commonly prescribed antifungal agent with a favorable safety profile." | 1.31 | Fluconazole-induced agranulocytosis with eosinophilia. ( Shriner, K; Wong-Beringer, A, 2000) |
| "A patient who was diagnosed as having agranulocytosis and thrombocytopenia after treatment with fluconazole was investigated and recovered after withdrawal of the antifungal therapy." | 1.28 | Agranulocytosis during treatment with fluconazole. ( Katahira, H; Matsushima, T; Murakami, H; Sakura, T; Sawamura, M; Tamura, J; Tsuchiya, J, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pasikhova, Y | 1 |
| Ludlow, SP | 1 |
| Sarcía-Ruiz, JC | 1 |
| Alvarez, C | 1 |
| Floristán, F | 1 |
| Hernández, I | 1 |
| Hernández, J | 1 |
| Alvarez Blanco, A | 1 |
| Ponton, J | 1 |
| Kliasova, GA | 1 |
| Kappe, R | 1 |
| Osterziel, KJ | 1 |
| Rüchel, R | 1 |
| Siehl, S | 1 |
| Viscoli, C | 1 |
| Castagnola, E | 1 |
| Van Lint, MT | 1 |
| Moroni, C | 1 |
| Garaventa, A | 1 |
| Rossi, MR | 1 |
| Fanci, R | 1 |
| Menichetti, F | 1 |
| Caselli, D | 1 |
| Giacchino, M | 1 |
| Congiu, M | 1 |
| Wong-Beringer, A | 1 |
| Shriner, K | 1 |
| Murakami, H | 1 |
| Katahira, H | 1 |
| Matsushima, T | 1 |
| Sakura, T | 1 |
| Tamura, J | 1 |
| Sawamura, M | 1 |
| Tsuchiya, J | 1 |
| Sotoyama, K | 1 |
| Rozenberg-Arska, M | 1 |
| Dekker, AW | 1 |
| Branger, J | 1 |
| Verhoef, J | 1 |
| Walsh, TJ | 2 |
| Aoki, S | 1 |
| Mechinaud, F | 1 |
| Bacher, J | 2 |
| Lee, J | 1 |
| Rubin, M | 1 |
| Pizzo, PA | 2 |
| Brammer, KW | 1 |
| Lee, JW | 1 |
| Lecciones, J | 1 |
| Kelly, P | 1 |
| Peter, J | 1 |
| Thomas, V | 1 |
| Van t Wout, JW | 1 |
| Mattie, H | 1 |
| van Furth, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for fluconazole and Agranulocytosis
| Article | Year |
|---|---|
Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amphotericin B; Antifungal Agents; Child; Child, Preschool | 1996 |
A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Amphotericin B; Femal | 1991 |
Management of fungal infection in neutropenic patients with fluconazole.
Topics: Adult; Agranulocytosis; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hematologic Diseases; | 1990 |
10 other studies available for fluconazole and Agranulocytosis
| Article | Year |
|---|---|
Fluconazole associated agranulocytosis and thrombocytopenia.
Topics: Aged; Agranulocytosis; Antifungal Agents; Female; Fluconazole; Humans; Thrombocytopenia | 2014 |
[Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia].
Topics: Agranulocytosis; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone | 1993 |
[The use of diflucan in myelotoxic agranulocytosis].
Topics: Acute Disease; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; | 1993 |
Fluconazole in patients at risk from invasive aspergillosis.
Topics: Adult; Agranulocytosis; Aspergillosis; Female; Fluconazole; Humans; Immunosuppression Therapy; Male; | 1993 |
Fluconazole-induced agranulocytosis with eosinophilia.
Topics: Aged; Agranulocytosis; Antifungal Agents; Eosinophilia; Fluconazole; Humans; Leukocyte Count; Male; | 2000 |
Agranulocytosis during treatment with fluconazole.
Topics: Adult; Agranulocytosis; Female; Fluconazole; Humans; Thrombocytopenia | 1992 |
[Countermeasure for infections with granulocytopenia].
Topics: Agranulocytosis; Aminoglycosides; Anti-Bacterial Agents; Candidiasis; Cephalosporins; Drug Therapy, | 1992 |
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.
Topics: Acute Disease; Agranulocytosis; Amphotericin B; Animals; Candidiasis; Chronic Disease; Disease Model | 1990 |
SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.
Topics: Agranulocytosis; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans | 1990 |
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candida albicans; Candidiasis; Fluconaz | 1989 |